Elsevier

American Heart Journal

Volume 150, Issue 3, September 2005, Pages 484-487
American Heart Journal

Clinical Investigation
Congestive Heart Failure
Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure

https://doi.org/10.1016/j.ahj.2004.11.016Get rights and content

Background

Extracellular matrix remodeling is thought to play an important role in the progression of heart failure (HF). Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are matrix-degrading enzymes that have been demonstrated to influence left ventricular properties and serve as targets of potential anti-remodeling agents. Herein we evaluated the potential significance of circulating MMP and TIMP levels in patients with congestive HF (CHF) speculating it may assume prognostic value.

Methods

Serum samples were obtained from 88 consecutive patients attending the outpatient HF clinic and analyzed for MMP-2, -3, -9, and TIMP-1 as well as N-terminal probrain natriuretic peptide (NT-ProBNP). Patients were followed up for the occurrence of either mortality or hospitalizations due to CHF or either of each.

Results

Circulating levels of MMP-2, -9, and TIMP-1 but not of MMP-3 were increased in patients with CHF as compared with age-matched controls. Only MMP-2 and NT-ProBNP levels correlated significantly with New York Heart Association class. Matrix metalloproteinase-2 and NT-ProBNP levels did not correlate. Patients with circulating MMP-2 above 352 ng/mL were 4.2 times more likely to die, 2.2 times more likely to be hospitalized because of CHF, and 2.3 times more likely to experience either of the 2 end points as compared with patients with MMP-2 concentrations below this threshold.

Both MMP-2 and NT-ProBNP were found to be independent predictors of mortality over a 24-month follow-up period.

Conclusions

Matrix metalloproteinase-2 but not MMP-3, -9, or TIMP-1 serum levels is an independent predictor of mortality in patients with CHF.

Section snippets

Materials and methods

We recruited 88 consecutive patients with advanced HF attending the outpatient HF clinic of the Tel Aviv Sourasky Medical Center. Patients with CHF within New York Heart Association (NYHA) functional classes II-IV were included. The local research ethics committee approved the study protocol and all patients gave written informed consent.

At baseline, patients had a full medical history taken, clinical examination performed, and NYHA class assigned. Patients were followed up every 1 to 3 months

Results

Mean age of the study patients was 72 ± 12 years, their median NYHA was 2.8, and their mean ejection fraction was 38% ± 14%. Sixty-three (72%) of the patients were males. Of the total 88 patients, 72 (82%) were receiving either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, 33 (38%) were on spironolactone, 58 (66%) were on β-blockers, and 24 (21%) were receiving digoxin.

Matrix metalloproteinase-2 serum levels significantly correlated with age (r = 0.33, P < .01,

Discussion

We have found that MMP-2, -9, and TIMP-1 serum levels were increased in patients with CHF as compared with control subjects. Levels of MMP-2 but not of the other MMPs or TIMP-1 correlated with the clinical status of the patients exhibited by their NYHA scores. These findings are in line with a recent publication,9 yet partially discordant with a study from Wilson et al10 showing that MMP-2 levels did not differ between patients with CHF and subjects with nonfailing hearts. These apparent

References (13)

There are more references available in the full text version of this article.

Cited by (106)

  • Associations between blood biomarkers, cardiac function and adverse outcome in a young tetralogy of Fallot cohort

    2022, International Journal of Cardiology
    Citation Excerpt :

    Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases and are controlled through tissue inhibitors of metalloproteinases (TIMPs) [49]. MMPs can degrade components of the extra cellular matrix (ECM) including collagens and play and important role in ECM remodelling [50–52]. In rat, canine and ovine models of acute pulmonary embolism pre-treatment with doxycycline -a non-selective MMP inhibitor- reduced RV dilation [52].

  • Matrix metalloproteinase-2-induced epidermal growth factor receptor transactivation impairs redox balance in vascular smooth muscle cells and facilitates vascular contraction

    2018, Redox Biology
    Citation Excerpt :

    Among other MMPs, mounting evidence implicates MMP-2 as a major player in disease processes, particularly in cardiovascular diseases [2,3]. In fact, increased circulating levels of MMP-2 have been associated with worse prognosis in patients with cardiovascular disease [4] and were suggested to predict mortality [5]. Moreover, acutely increasing circulating MMP-2 levels significantly impaired both cardiac and vascular function [6], although the precise mechanisms explaining these findings have not been fully elucidated.

  • The application of collagen-related biomarkers in heart failure

    2023, Chinese Journal of Laboratory Medicine
View all citing articles on Scopus
1

Affiliated to the Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel.

View full text